https://www.selleckchem.com/products/apd334.html
Outcomes were also compared in women with advanced prolapse versus stage II prolapse. RESULTS Success did not differ between groups (ULS 58.2% [57/117] versus SSLF 58.5% [55/113], aOR 1.0 [0.5-1.8]). No differences were detected in individual success components (p 0.05 for all components). Prolapse symptom severity scores improved in both interventions with no intergroup differences (p = 0.82). Serious adverse events did not differ (ULS 19.7% versus SSLF 16.8%, aOR 1.2 [0.6-2.4]). Success was lower in women with advanced prolapse co
Like
Comment
Share
